Clinical Trial Update: VEL-101 to Prevent Rejection After Kidney Transplantation [Phase 2]

View source ↗

Summary

VEL-101 is being studied in a Phase 2 trial to prevent rejection in kidney transplant recipients; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transplant Rejection

Drugs mentioned

• VEL-101

Snippet

Sponsor: Veloxis Pharmaceuticals | Conditions: Transplantation, Kidney | Phase 2 | Status: NOT_YET_RECRUITING